查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032430

非酒精性脂肪性肝炎市場：按藥物類型、疾病原因、銷售管道、最終用戶和地區分類（2026-2034 年）

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球非酒精性脂肪性肝炎（NASH）市場規模達24億美元。展望未來，IMARC Group預測，該市場將從2026年到2034年以22.06%的複合年成長率成長，到2034年達到149億美元。 NASH盛行率上升、人們對早期診斷和治療的認知不斷提高，以及人工智慧（AI）和機器學習（ML）技術的應用，是推動市場成長的主要因素。

非酒精性脂肪性肝炎 (NASH) 是進行性非酒精性脂肪肝 (NAFLD)，由胰島素阻抗、過重和METABOLIC INC.症候群引起。症狀包括疲倦、體重減輕、黃疸、皮膚搔癢、蜘蛛痣、肝腫大、注意力不集中、體液儲存、腹部不適（如疼痛和腫脹）。診斷方法包括身體檢查、血液檢查、切片檢查、磁振造影(MRI)、超音波和電腦斷層掃描 (CT)。 NASH 的治療包括藥物治療、肝臟移植以及各種生活方式干涉，例如規律運動和健康飲食。這些治療方法有助於減少肝臟脂肪堆積、改善肝功能、抑制發炎並最大限度地減少肝損傷。它們還能提高患者的生活品質，改善長期預後，並有助於更好地控制其他健康問題，例如肥胖和高血壓。

非酒精性脂肪性肝炎（NASH）市場趨勢：

由於遺傳因素、缺乏運動、不健康的飲食習慣、肥胖和第2型糖尿病等原因，非酒精性脂肪性肝炎（NASH）的盛行率不斷上升，這是市場成長的主要驅動力之一。因此，NASH治療因其緩解症狀、延長壽命、預防過早死亡、改善肝臟健康和促進整體健康等功效而日益被患者接受，這也是推動市場成長的動力。此外，大眾對早期診斷和治療NASH重要性的認知不斷提高，有助於降低醫療成本、避免肝臟移植以及預防高血壓、心血管疾病（CVD）、癌症、肝功能衰竭和肝衰竭等併發症，從而促進市場成長。同時，磁振造影（MRI）和瞬時彈性成像（TE）等非侵入性影像技術在NASH監測和診斷中的應用，透過提高患者舒適度、增強治療依從性、降低併發症風險和改善臨床療效，也對市場成長產生了積極影響。最後，將人工智慧（AI）和機器學習（ML）應用於開發個人化療法、提高診斷準確性和預測疾病進展的努力，也是推動市場成長的因素。此外，政府主導的各項旨在提供高品質治療和支持先進治療方法研發的措施正在推動市場成長。預計推動市場成長的其他因素包括老年人口成長、醫療保健支出增加、積極的研發活動、醫療保健產業的顯著成長以及對非侵入性治療方法的需求不斷成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球非酒精性脂肪性肝炎市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類型分類

  • 維生素E和PIOGLITAZONE
  • Ocaliva
  • Elafibranor
  • 塞隆塞提布
  • 塞尼克利維洛克
  • 其他

第7章 市場區隔：依疾病原因分類

  • 高血壓
  • 心臟病
  • 高血脂症
  • 2型糖尿病
  • 肥胖

第8章 市場區隔：依銷售管道分類

  • 醫院藥房
  • 線上提供者
  • 零售藥房

第9章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 居家醫療環境

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章：促進、抑制與機遇

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Algernon Pharmaceuticals
    • Galmed Pharmaceuticals Ltd
    • Intercept Pharmaceuticals Inc.
    • Zydus Lifesciences Limited
Product Code: SR112026A7397

The global non-alcoholic steatohepatitis (NASH) market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 14.9 Billion by 2034, exhibiting a growth rate (CAGR) of 22.06% during 2026-2034. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI) , ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

NON-ALCOHOLIC STEATOHEPATITIS (NASH) MARKET TRENDS:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.

KEY MARKET SEGMENTATION:

Drug Type Insights:

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others

Disease Cause Insights:

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity

Sales Channel Insights:

  • Hospital Pharmacy
  • Online Providers
  • Retail Pharmacy

End User Insights:

  • Hospitals
  • Clinics
  • Homecare Settings

Regional Insights:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2025
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2025
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2025
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2025
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million USD), 2026-2034
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million USD), 2026-2034
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players